This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Teva Pharmaceutical Industries Ltd.
Drug Names(s): KT7515
Description: CEP-1347 is a novel compound that inhibits activation of mixed lineage kinases (MLKs), which have been shown to play a key role in apoptosis.
Cephalon and Lundbeck
In June 1999, Cephalon and H. Lundbeck A/S entered into a colloboration to discover, develop and market products to treat neurodegenerative diseases. Initially, the program sought to advance CEP-1347 into clinical development for the treatment of Parkinson's disease. Under the terms of this agreement, Cephalon is to receive from Lundbeck approximately $40 million, which includes an upfront license fee, research and milestone payments, and an equity investment of Cephalon stock. Lundbeck is to support research and share the costs of developing CEP-1347 and any other molecules that emerge from the research program. Lundbeck is to obtain Cephalon's commercial rights in Europe and certain other territories, and was to pay Cephalon a royalty on sales in those territories. Cephalon is to retain exclusive rights in the United States. Kyowa Hakko Kogyo Co. Ltd. is to remain Cephalon's partner for CEP-1347 in the rest of the world.
Cephalon and...See full deal structure in Biomedtracker
Partners: H. Lundbeck A/S Amgen, Inc. Kyowa Hakko Kirin Co., Ltd.
Additional information available to subscribers only: